Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Serum MiRNA-27a as potential diagnostic nucleic marker for breast cancer.

Swellam M, Zahran RFK, Ghonem SA, Abdel-Malak C.

Arch Physiol Biochem. 2019 May 30:1-7. doi: 10.1080/13813455.2019.1616765. [Epub ahead of print]

PMID:
31145011
2.

Clinical significance of blood-based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: Comparative to conventional tumor markers.

Swellam M, Ramadan A, El-Hussieny EA, Bakr NM, Hassan NM, Sobeih ME, EzzElArab LR.

J Cell Biochem. 2019 Aug;120(8):12321-12330. doi: 10.1002/jcb.28496. Epub 2019 Mar 1.

PMID:
30825229
3.

Clinical aspects of circulating miRNA-335 in breast cancer patients: A prospective study.

Swellam M, Mahmoud MS, Hashim M, Hassan NM, Sobeih ME, Nageeb AM.

J Cell Biochem. 2019 Jun;120(6):8975-8982. doi: 10.1002/jcb.28168. Epub 2018 Dec 3.

PMID:
30506730
4.

Evaluation of Osteopontin and Pokémon genes expression in hepatitis C virus-associated hepatocellular carcinoma.

El-Khazragy N, Khalifa MM, Salem AM, Swellam M, Hegazy M.

J Cell Biochem. 2018 Nov 11. doi: 10.1002/jcb.28018. [Epub ahead of print]

PMID:
30417409
5.

miRNA-155 and miRNA-181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia.

El-Khazragy N, Noshi MA, Abdel-Malak C, Zahran RF, Swellam M.

J Cell Biochem. 2019 Apr;120(4):6315-6321. doi: 10.1002/jcb.27918. Epub 2018 Oct 25.

PMID:
30362157
6.

Role of some circulating MiRNAs on breast cancer diagnosis.

Swellam M, Zahran RFK, Abo El-Sadat Taha H, El-Khazragy N, Abdel-Malak C.

Arch Physiol Biochem. 2018 Jun 20:1-9. doi: 10.1080/13813455.2018.1482355. [Epub ahead of print]

PMID:
29925280
7.

Potential diagnostic role of circulating MiRNAs in breast cancer: Implications on clinicopathological characters.

Swellam M, El Magdoub HM, Hassan NM, Hefny MM, Sobeih ME.

Clin Biochem. 2018 Jun;56:47-54. doi: 10.1016/j.clinbiochem.2018.04.013. Epub 2018 Apr 19.

PMID:
29679553
8.

Aberrant Expression of Some Circulating miRNAs in Childhood Acute Lymphoblastic Leukemia.

Swellam M, Hashim M, Mahmoud MS, Ramadan A, Hassan NM.

Biochem Genet. 2018 Aug;56(4):283-294. doi: 10.1007/s10528-018-9844-y. Epub 2018 Feb 19.

PMID:
29460192
9.

Cytotoxic effect of ferrimagnetic glass-ceramic nanocomposites on bone osteosarcoma cells.

Gamal-Eldeen AM, Abdel-Hameed SAM, El-Daly SM, Abo-Zeid MAM, Swellam MM.

Biomed Pharmacother. 2017 Apr;88:689-697. doi: 10.1016/j.biopha.2017.01.113. Epub 2017 Jan 30.

PMID:
28152478
10.

Clinical impact of circulating microRNAs as blood-based marker in childhood acute lymphoblastic leukemia.

Swellam M, El-Khazragy N.

Tumour Biol. 2016 Aug;37(8):10571-6. doi: 10.1007/s13277-016-4948-7. Epub 2016 Feb 9.

PMID:
26857279
11.

Apolipoprotein E genotyping in Egyptian diabetic nephropathy patients.

Atta MI, Abo Gabal K, El-Hadidi K, Swellam M, Genina A, Zaher NF.

IUBMB Life. 2016 Jan;68(1):58-64. doi: 10.1002/iub.1460. Epub 2015 Dec 11.

12.

Aberrant methylation of APC and RARβ2 genes in breast cancer patients.

Swellam M, Abdelmaksoud MD, Sayed Mahmoud M, Ramadan A, Abdel-Moneem W, Hefny MM.

IUBMB Life. 2015 Jan;67(1):61-8. doi: 10.1002/iub.1346. Epub 2015 Feb 11.

13.

Clinical implications of proteolytic activity imbalance in breast cancer diagnosis.

Swellam M, Soliman HA, Abdelmaksoud MD, Nageeb AM, El Arab LR, Boshnak H.

Cancer Biomark. 2014;14(6):409-17. doi: 10.3233/CBM-140428.

PMID:
25335732
14.

Anti-mullerian and androgens hormones in women with polycystic ovary syndrome undergoing IVF/ICSI.

Swellam M, Khaial A, Mosa T, El-Baz H, Said M.

Iran J Reprod Med. 2013 Nov;11(11):883-90.

15.
16.

Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.

El-Arab LR, Swellam M, El Mahdy MM.

J Egypt Natl Canc Inst. 2012 Mar;24(1):15-22. doi: 10.1016/j.jnci.2011.12.002. Epub 2012 Jan 17.

17.

Association of nonalcoholic fatty liver disease with a single nucleotide polymorphism on the gene encoding leptin receptor.

Swellam M, Hamdy N.

IUBMB Life. 2012 Feb;64(2):180-6. doi: 10.1002/iub.597. Epub 2012 Jan 3.

18.

Aberrant methylation of RARbeta2 and APC genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial bladder cancer.

Eissa S, Swellam M, El-Khouly IM, Kassim SK, Shehata H, Mansour A, Esmat M, Nossier AI, Hamdy MA, Awad NM, El-Ahmady O.

Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1657-64. doi: 10.1158/1055-9965.EPI-11-0237. Epub 2011 Jun 15.

19.
20.

The clinical relevance of urine-based markers for diagnosis of bladder cancer.

Eissa S, Swellam M, Amin A, Balbaa ME, Yacout GA, El-Zayat TM.

Med Oncol. 2011 Jun;28(2):513-8. doi: 10.1007/s12032-010-9422-6. Epub 2011 Mar 25.

PMID:
21437743
21.

Potential influence of interleukin-1 receptor antagonist gene polymorphism on knee osteoarthritis risk.

Swellam M, Mahmoud MS, Samy N, Gamal AA.

Dis Markers. 2010;28(5):299-305. doi: 10.3233/DMA-2010-0708.

22.

Clinical implications of adiponectin and inflammatory biomarkers in type 2 diabetes mellitus.

Swellam M, Sayed Mahmoud And M, Abdel-Fatah Ali A.

Dis Markers. 2009;27(6):269-78. doi: 10.3233/DMA-2009-0672.

23.

Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.

Eissa S, Swellam M, Shehata H, El-Khouly IM, El-Zayat T, El-Ahmady O.

J Urol. 2010 Feb;183(2):493-8. doi: 10.1016/j.juro.2009.10.024. Epub 2009 Dec 14.

PMID:
20006858
24.

Emerging role of endothelial and inflammatory markers in preeclampsia.

Swellam M, Samy N, Wahab SA, Ibrahim MS.

Dis Markers. 2009;26(3):127-33. doi: 10.3233/DMA-2009-0622.

25.

A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot.

Eissa S, Swellam M, Labib RA, El-Zayat T, El Ahmady O.

J Urol. 2009 Mar;181(3):1353-60. doi: 10.1016/j.juro.2008.10.102. Epub 2009 Jan 29.

PMID:
19185322
26.

Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer.

Eissa S, Zohny SF, Swellam M, Mahmoud MH, El-Zayat TM, Salem AM.

Clin Biochem. 2008 Nov;41(16-17):1335-41. doi: 10.1016/j.clinbiochem.2008.08.085. Epub 2008 Sep 9.

PMID:
18804101
27.

Prognostic value of cell-cycle regulators and cellular biomarkers in laryngeal squamous cell carcinoma.

Swellam M, El-Arab LR, Adly A.

Clin Biochem. 2008 Sep;41(13):1059-66. doi: 10.1016/j.clinbiochem.2008.06.001. Epub 2008 Jun 10.

PMID:
18602381
28.
29.

Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer.

Eissa S, Swellam M, Ali-Labib R, Mansour A, El-Malt O, Tash FM.

J Urol. 2007 Sep;178(3 Pt 1):1068-72. Epub 2007 Jul 20.

PMID:
17644139
30.
31.

Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.

Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM.

Eur Urol. 2007 Nov;52(5):1388-96. Epub 2007 Apr 10.

PMID:
17466450
32.

Deletions of p15 and p16 in schistosomal bladder cancer correlate with transforming growth factor-alpha expression.

Swellam M, El-Aal AA, AbuGabel KM.

Clin Biochem. 2004 Dec;37(12):1098-104.

PMID:
15589816
33.

Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients.

Swellam M, Ismail M, Eissa S, Hamdy M, Mokhtar N.

IUBMB Life. 2004 Aug;56(8):483-90.

34.

Comparison of cytokeratin 20 RNA and angiogenin in voided urine samples as diagnostic tools for bladder carcinoma.

Eissa S, Kenawy G, Swellam M, El-Fadle AA, Abd El-Aal AA, El-Ahmady O.

Clin Biochem. 2004 Sep;37(9):803-10.

PMID:
15329320
35.

Incidence of Bcl-2 expression in bladder cancer: relation to schistosomiasis.

Swellam M, Abd-Elmaksoud N, Halim MH, Khatab H, Khiry H.

Clin Biochem. 2004 Sep;37(9):798-802. Erratum in: Clin Biochem. 2004 Dec;37(12):1121.

PMID:
15329319
36.

Diagnostic value of urinary molecular markers in bladder cancer.

Eissa S, Swellam M, el-Mosallamy H, Mourad MS, Hamdy N, Kamel K, Zaglol AS, Khafagy MM, el-Ahmady O.

Anticancer Res. 2003 Sep-Oct;23(5b):4347-55.

PMID:
14666650
37.

Supplemental Content

Loading ...
Support Center